People with fatty liver disease and advanced liver scarring tend to have higher levels of thyroid-stimulating hormone than those with mild or no scarring, even when thyroid function is technically normal.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of longitudinal studies would determine whether the TSH-fibrosis gradient is consistent across populations and whether the magnitude of difference is clinically meaningful.
Systematic review and meta-analysis of all prospective studies reporting mean TSH levels in MAFLD patients stratified by fibrosis stage (F0-F1, F2, F3-F4) using biopsy or elastography, with pooled mean differences and heterogeneity analysis.
An RCT would test whether lowering TSH reduces fibrosis progression, thereby determining if the gradient reflects a causal relationship.
Double-blind RCT of 300 MAFLD patients with TSH 2.5–4.5 mIU/L and FIB-4 1.3–2.67, randomized to levothyroxine (target TSH 1.5–2.0) vs. placebo for 2 years, with serial MRE to measure change in liver stiffness as primary outcome.
A prospective cohort would determine whether higher baseline TSH predicts steeper fibrosis progression over time, confirming the gradient as predictive.
Prospective cohort of 1,500 MAFLD patients with baseline TSH and FIB-4, followed for 5 years with annual FIB-4 and biennial elastography, analyzing whether TSH quartiles predict rate of fibrosis progression.
A case-control study comparing TSH levels across fibrosis stages would confirm whether TSH increases progressively with fibrosis severity.
Case-control study of 600 MAFLD patients with biopsy-proven fibrosis stages (F0-F1, F2, F3-F4), matched for age, sex, BMI, and diabetes, measuring TSH at time of biopsy to compare mean levels across stages.
A cross-sectional study can only show whether TSH levels differ across fibrosis stages at a single time point, as done in this study.
Cross-sectional analysis of 5,000 MAFLD patients with TSH measured and fibrosis staged via FIB-4/NFS or elastography, comparing mean TSH across fibrosis categories.